Outcome of novel oral anticoagulant versus warfarin in frail elderly patients with atrial fibrillation: a systematic review and meta-analysis of retrospective studies

References

• Wolf PA, Abbott, PD, Kannel, WB et al. Atrial fibrillation: a major contributor to stroke in the elderly. Arch Internal Med. 1987;147(9):1561–1564
   PubMedGoogle Scholar
• Andrade JG, Aguilar M, Atzema C, et al. The 2020 Canadian cardiovascular society/Canadian heart rhythm society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol. 2020;36(12):1847–1948. DOI:10.1016/j.cjca.2020.09.001
   PubMed Web of Science ®Google Scholar
• Shimada H, Makizako H, Doi T, et al. Combined prevalence of frailty and mild cognitive impairment in a population of elderly Japanese people. J Am Med Dir Assoc. 2013;14(7):518–524. DOI:10.1016/j.jamda.2013.03.010
   PubMed Web of Science ®Google Scholar
• Villacampa-Fernandez P, Navarro-Pardo E, Tarin JJ, et al. Frailty and multimorbidity: two related yet different concepts. Maturitas. 2017;95:31–35.
   PubMed Web of Science ®Google Scholar
• Annoni G, Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol. 2016;13(3):226–232.
   PubMedGoogle Scholar
• Gullón A, Formiga F, Díez-Manglano J, et al. Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation. Intern Emerg Med. 2019;14(1):59–69. DOI:10.1007/s11739-018-1938-3
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962. DOI:10.1093/eurheartj/ehw210
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14.
   PubMed Web of Science ®Google Scholar
• Bauersachs RM, Herold J. Oral anticoagulation in the elderly and frail. Hämostaseologie. 2020;40(1):74–83.
   PubMed Web of Science ®Google Scholar
• Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127(6):2049–2056. DOI:10.1378/chest.127.6.2049
   PubMed Web of Science ®Google Scholar
• Wilkinson C, Todd O, Clegg A, et al. Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis. Age Ageing. 2019;48(2):196–203. DOI:10.1093/ageing/afy180
   PubMed Web of Science ®Google Scholar
• Malik AH, Yandrapalli S, Aronow WS, et al. Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol. 2019;123(12):2051–2057. DOI:10.1016/j.amjcard.2019.02.060
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian AV, Kang AL, et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med. 2021;289(1):42–52. DOI:10.1111/joim.13140
   PubMed Web of Science ®Google Scholar
• Kim D, Yang PS, Sung JH, et al. Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke. 2022;53(6):1873–1882. DOI:10.1161/STROKEAHA.121.036757
   PubMed Web of Science ®Google Scholar
• Martinez BK, Sood NA, Bunz TJ, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8). DOI:10.1161/JAHA.118.008643
   Web of Science ®Google Scholar
• Hohmann C, Hohnloser SH, Jacob J, et al. Non-vitamin k oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost. 2019;119(6):971–980. DOI:10.1055/s-0039-1683422
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341. DOI:10.1016/j.ijsu.2010.02.007
   PubMed Web of Science ®Google Scholar
• Kahn SR, Susan Solymoss M, Lamping DL, et al. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med. 2020;15(6):425–429. DOI:10.1046/j.1525-1497.2000.06419.x
   Google Scholar
• Bergman H, Ferrucci L, Guralnik J, et al. Frailty: an emerging research and clinical paradigm—issues and controversies. J Gerontol Ser A. 2007;62(7):731–736. DOI:10.1093/gerona/62.7.731
   PubMed Web of Science ®Google Scholar
• Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–713. DOI:10.1016/j.cell.2014.10.039
   PubMed Web of Science ®Google Scholar
• Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14(12):877–882. DOI:10.1016/j.jamda.2013.05.009
   PubMed Web of Science ®Google Scholar
• Rattan SIS. Biogerontology: research status, challenges and opportunities. Acta Biomed. 2018;89(2):291–301.
   PubMedGoogle Scholar
• Doody P, Asamane EA, Aunger JA, et al. The prevalence of frailty and pre-frailty among geriatric hospital inpatients and its association with economic prosperity and healthcare expenditure: a systematic review and meta-analysis of 467,779 geriatric hospital inpatients. Ageing Res Rev. 2022;80:101666.
   PubMed Web of Science ®Google Scholar
• Fried LP, Tangen CM, J W, et al. Frailty in Older Adults: evidence for a Phenotype. J Gerontol. 2001;56(3):M146–156. DOI:10.1093/gerona/56.3.M146
   Google Scholar
• Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing. 2018;47(2):193–200.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manas L, Feart C, Mann G, et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. J Gerontol A. 2013;68(1):62–67. DOI:10.1093/gerona/gls119
   Google Scholar
• Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–495. DOI:10.1503/cmaj.050051
   PubMed Web of Science ®Google Scholar
• Gilbert T, Neuburger J, Kraindler J, et al. Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study. Lancet. 2018;391(10132):1775–1782. DOI:10.1016/S0140-6736(18)30668-8
   PubMed Web of Science ®Google Scholar
• Segal JB, Chang H-Y, Du W, et al. Development of a Claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care. 2017;55(7):716–722. DOI:10.1097/MLR.0000000000000729
   PubMed Web of Science ®Google Scholar
• Sobhani A, Fadayevatan R, Sharifi F, et al. The conceptual and practical definitions of frailty in older adults: a systematic review. J Diabetes Metab Disord. 2021;20(2):1975–2013. DOI:10.1007/s40200-021-00897-x
   PubMed Web of Science ®Google Scholar
• Bibas L, Levi M, Bendayan M, et al. Therapeutic interventions for frail elderly patients: part I. Published randomized trials. Prog Cardiovasc Dis. 2014;57(2):134–143. DOI:10.1016/j.pcad.2014.07.004
   PubMed Web of Science ®Google Scholar
• Gharacholou SM, Tashiro T, Cha SS, et al. Echocardiographic indices associated with frailty in adults ≥65 years. Am J Cardiol. 2015;116(10):1591–1595. DOI:10.1016/j.amjcard.2015.08.023
   PubMed Web of Science ®Google Scholar
• Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;35:63–73.
   PubMed Web of Science ®Google Scholar
• Bizhanov KA, Аbzaliyev KB, Baimbetov AK, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical complications (literature review). J Cardiovasc Electrophysiol. 2022;34(1):153–165. DOI:10.1111/jce.15759
   PubMed Web of Science ®Google Scholar
• Fumagalli S, Tarantini F, Guarducci L, et al. Atrial fibrillation is a possible marker of frailty in hospitalized patients: results of the GIFA study. Aging Clin Exp Res. 2010;22(2):129–133. DOI:10.1007/BF03324785
   PubMed Web of Science ®Google Scholar
• Liao JN, Chan YH, Kuo L, et al. Optimal anticoagulation in elderly patients with atrial fibrillation: which drug at which dose? Kardiol Pol. 2022;80(2):128–136. DOI:10.33963/KP.a2022.0046
   PubMed Web of Science ®Google Scholar
• Nguyen TN, Morel-Kopp MC, Pepperell D, et al. The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study. Aging Clin Exp Res. 2017;29(6):1129–1138. DOI:10.1007/s40520-017-0733-8
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: chest guideline and expert panel report. Chest. 2018;154(5):1121–1201. DOI:10.1016/j.chest.2018.07.040
   PubMed Web of Science ®Google Scholar
• Kim SW, Yoon SJ, Choi JY, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch Gerontol Geriatr. 2017;70:1–7.
   PubMed Web of Science ®Google Scholar
• Perera V, Bajorek BV, Matthews S, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38(2):156–162. DOI:10.1093/ageing/afn293
   PubMed Web of Science ®Google Scholar
• Turagam MK, Velagapudi P, Flaker GC. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interventions Aging. 2015;10:1431–1444.
   PubMed Web of Science ®Google Scholar
• van Riet-Nales DA, van den Bemt B, van Bodegom D, et al. Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. Br J Clin Pharmacol. 2022;88(4):1500–1514. DOI:10.1111/bcp.15207
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. DOI:10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Szcerba, Ewa, Patel MR [: Mahaffey KW, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , et al. . N Engl J Med. 2011;365(17):1557–1559. . .
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. DOI:10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban once daily, Oral, Direct Factor Xa Inhibition compared with Vitamin K Antagonism for prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014;130(2):138–146. DOI:10.1161/CIRCULATIONAHA.113.005008
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864–1872. DOI:10.1093/eurheartj/ehu046
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J. 2014;78(6):1349–1356. DOI:10.1253/circj.CJ-13-1324
   PubMed Web of Science ®Google Scholar
• Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial. J Am Heart Assoc. 2016;5(5). DOI:10.1161/JAHA.116.003432
   Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372. DOI:10.1161/CIRCULATIONAHA.110.004747
   PubMed Web of Science ®Google Scholar
• Grymonprez M, Steurbaut S, De Backer TL, et al. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;11:583311.
   PubMed Web of Science ®Google Scholar
• Blodgett J, Theou O, Kirkland S, et al. Frailty in NHANES: comparing the frailty index and phenotype. Arch Gerontol Geriatr. 2015;60(3):464–470. DOI:10.1016/j.archger.2015.01.016
   PubMed Web of Science ®Google Scholar